Article
Urology & Nephrology
J. Kellogg Parsons, Peter A. Pinto, Christian P. Pavlovich, Edward Uchio, Mike N. Nguyen, Hyung L. Kim, James L. Gulley, Houssein Abdul Sater, Christina Jamieson, Chiu-Hsieh Hsu, Malgorzata Wojtowicz, Margaret House, Jeffrey Schlom, Renee N. Donahue, William L. Dahut, Ravi A. Madan, Shania Bailey, Sara Centuori, Julie E. Bauman, Howard L. Parnes, H. -H. Sherry Chow
Summary: This study investigated the immunologic response to the PROSTVAC vaccine and the clinical indicators of disease progression in patients with localized prostate cancer on active surveillance. The results showed that the PROSTVAC vaccine did not have better efficacy compared to the control group. Despite the negative findings, this is the first study to demonstrate the feasibility and acceptability of immunotherapy in the active surveillance setting for prostate cancer.
EUROPEAN UROLOGY FOCUS
(2023)
Review
Oncology
Hao Liang, Yang Liu, Jiao Guo, Maoyang Dou, Xiaoyi Zhang, Liyong Hu, Jun Chen
Summary: Prostate cancer is a common malignant cancer of the male genitourinary system. Immunotherapy has shown initial success in the treatment of advanced prostate cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Carson R. Reynolds, Son Tran, Mohit Jain, Aru Narendran
Summary: Neoantigen-based immunotherapeutic approaches have become an effective and highly tolerable therapeutic option in the rapidly evolving field of cancer treatment.
Review
Immunology
Sarah I. M. Sutherland, Xinsheng Ju, L. G. Horvath, Georgina J. Clark
Summary: Despite the success of using checkpoint inhibitors to reprim T cells to recognize tumors in certain malignancies, including melanoma, lung, and renal cell carcinoma, many tumors, such as prostate cancer, remain resistant to such treatment. DC-based immunotherapy, such as Sipuleucel-T, has shown improved overall survival in prostate cancer, but further research into DC vaccines has been limited. Understanding the immunosuppressive environment of prostate cancer and developing new vaccine strategies that can overcome this environment is essential for future success in immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Xuyan Zhou, Haiying Lian, Hongpeng Li, Meiling Fan, Wei Xu, Ye Jin
Summary: Immunotherapy is a promising method for treating cervical cancer, but its clinical application is limited by adverse effects. Nanotechnology offers potential advantages in cervical cancer treatment by enhancing drug delivery, reducing adverse effects, and improving the immune microenvironment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, Research & Experimental
Zacharias Wijfjes, Floris J. van Dalen, Camille M. Le Gall, Martijn Verdoes
Summary: This article reviews the mouse and human receptors studied as targets for therapeutic vaccines and discusses how antibody and ligand conjugates targeting affect antigen presentation. The aim is to delineate how targeting distinct receptors affects antigen presentation and vaccine efficacy, guiding target selection for future therapeutic vaccine development.
MOLECULAR PHARMACEUTICS
(2023)
Review
Oncology
Canling Lin, Yonghui Chen, Liji Shi, Huarong Lin, Hongmei Xia, Weihua Yin
Summary: Prostate cancer is a significant disease worldwide, and its incidence is increasing in China. Despite the efficacy of chemotherapy agents, treatment failure can occur, leading to castration-resistant prostate cancer. Due to limited treatment options, bio-immunotherapy targeting the prostate microenvironment has become an important option for advanced prostate cancer. This study investigates the role of three types of bio-immunotherapies in castrate-resistant prostate cancer, providing insights for clinical treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Bisheng Cheng, Chen Tang, Junjia Xie, Qianghua Zhou, Tianlong Luo, Qiong Wang, Hai Huang
Summary: This study established a novel predictive model for prostate cancer based on cuproptosis-related genes, providing insights into patient prognosis and highlighting the importance of PDHA1 in cancer progression. High expression of PDHA1 was associated with disease progression, drug sensitivity, and therapeutic response in prostate cancer patients.
Review
Pharmacology & Pharmacy
Matthew D. Kerr, David A. McBride, Arun K. Chumber, Nisarg J. Shah
Summary: A deeper understanding of the immunostimulatory properties of cytoreductive therapies has supported their utility in combination therapies involving cancer vaccines to induce a durable anti-tumor immune response. Combination therapies may have synergies depending on the identity of the cytotoxic agent, vaccine target, dosing schedule, and cancer type, suggesting that combining cancer vaccines with immunomodulatory cytoreductive therapy is a promising strategy for cancer therapy.
EXPERT OPINION ON DRUG DISCOVERY
(2021)
Article
Biochemistry & Molecular Biology
Erik N. Taylor, Colin M. Wilson, Stefan Franco, Henning De May, Lorel Y. Medina, Yirong Yang, Erica B. Flores, Eric Bartee, Reed G. Selwyn, Rita E. Serda
Summary: This study utilizes simultaneous [F-18]FDG-PET/MRI for spatial and quantitative analysis of tumor burden to monitor therapeutic responses to ovarian cancer immunotherapy, providing a possible roadmap for accurate monitoring of therapeutic responses to cancer immunotherapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ravi A. Madan, Marijo Bilusic, Mark N. Stein, Renee N. Donahue, Philip M. Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M. Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D. Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley
Summary: This study compared the efficacy of Flutamide with or without PROSTVAC in patients with non-metastatic castration resistant prostate cancer, and the results showed that the addition of PROSTVAC did not improve patient outcomes.
Review
Pharmacology & Pharmacy
Shih-Cheng Pao, Mu-Tzu Chu, Shuen-Iu Hung
Summary: Cancer immunotherapy has become indispensable in cancer treatment, with a focus on targeting tumor-specific antigens or neoantigens. Advanced technologies have allowed for the identification and application of neoantigens in cancer vaccines. Therapeutic vaccines have shown success in activating the immune system to kill cancer cells.
Article
Oncology
Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylosmaki, Sari Pesonen, Rui M. M. Branca, Janne Lehtio, Vincenzo Cerullo
Summary: This study explores a novel oncolytic adenovirus vaccine platform as immunotherapy in resistant tumors, customized for improved tumor targeting based on experimentally discovered tumor antigens; the pipeline may be applied for designing personalized therapeutic cancer vaccines, which is crucial for broader design and utility of therapeutic cancer vaccines. The study integrates immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy, showing promising control of established tumors using a flexible and specific tumor targeting oncolytic adenovirus platform.
Review
Oncology
Felicia Maria Maselli, Francesco Giuliani, Carmelo Laface, Martina Perrone, Assunta Melaccio, Pierluigi De Santis, Anna Natalizia Santoro, Chiara Guarini, Maria Laura Iaia, Palma Fedele
Summary: Prostate cancer is the most common tumor in men and is initially sensitive to androgen deprivation therapy. However, castration resistance eventually develops, and new treatments are urgently needed for metastatic castration-resistant prostate cancer (mCRPC) patients due to poor prognosis.
Article
Oncology
Marijo Bilusic, Nicole J. Toney, Renee N. Donahue, Susan Wroblewski, Matthew Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman
Summary: This study investigated the effects of metformin in prostate cancer treatment through a phase 2 trial. The results showed that metformin monotherapy induced modest declines in serum PSA levels in some patients and had an impact on immune cell subsets. However, the combination of metformin and bicalutamide did not improve the rate of achieving undetectable PSA at 32 weeks.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan
Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley
Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Diana C. Lopez, Yvette L. Robbins, Joshua T. Kowalczyk, Wiem Lassoued, James L. Gulley, Markku M. Miettinen, Gary L. Gallia, Clint T. Allen, James W. Hodge, Nyall R. London Jr
Summary: This study comprehensively evaluates the tumor immune microenvironment (TIME) of chordoma using multispectral immunofluorescence (MIF). The results show that myeloid cells significantly infiltrate chordoma tumor parenchyma, while T cells tend to be excluded from the tumor parenchyma and have higher stromal infiltration. This suggests that future immunotherapy strategies for chordoma should aim to decrease myeloid cell suppressive function and enhance cytotoxic T cell and NK cell killing.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Mary Helen Barcellos-Hoff, James L. Gulley
Summary: Despite the increasing number of TGFI3 inhibitors tested in cancer patients, there has been no clinical benefit achieved yet. The main obstacle to effective TGFI3 inhibition is the diverse mechanisms by which TGFI3 promotes tumor growth. TGFI3 is involved in regulating DNA repair and immune suppression, which can be used to synergize genotoxic therapy and immunotherapy for the benefit of cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg, Mark J. Ratain
Summary: Atezolizumab, a humanized monoclonal antibody against PD-L1, was approved in 2016. Standard dose regimens result in high plasma concentrations, indicating the need for alternative dosing strategies to reduce exposure burden.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Oncology
Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz
Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.
Article
Oncology
Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Julio Peguero, Guy Jerusalem, Nicolas Penel, Esma Saada-Bouzid, Pilar Garrido, Christoph Helwig, George Locke, Laureen S. Ojalvo, James L. Gulley
Summary: Bintrafusp alfa showed some clinical activity and a manageable safety profile in heavily pretreated NSCLC patients.
Article
Oncology
Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley
Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.
Article
Oncology
Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen
Summary: PSMA expression is maintained in all stages of prostate cancer. In a phase 1 study, a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells showed manageable cytokine release syndrome and temporary decline in PSA in patients with metastatic castration-resistant prostate cancer. Treatment-related deaths and radiographic responses were not observed. PSMA is a potential therapeutic target for T-cell redirection in prostate cancer.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Michael B. Atkins, Paolo A. Ascierto, David Feltquate, James L. Gulley, Douglas B. Johnson, Nikhil Khushalani, Jeffrey Sosman, Timonthy A. Yap, Harriet Kluger, Ryan J. Sullivan, Hussein Tawbi
Summary: Immunotherapy alone does not work for all tumors, so combining it with signal transduction inhibitors, such as antiangiogenic therapies, can enhance its effectiveness. Combination therapies with immunotherapy have shown improved antitumor activity in various solid tumor settings and have received regulatory approval for the treatment of several types of cancer. However, many patients still experience progression after combination treatment, highlighting the need for new strategies to address resistance to immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Ryan Chang, James L. Gulley, Lawrence Fong
Summary: Immunotherapies, such as immune checkpoint inhibitors and cellular therapies, have revolutionized cancer treatment, but the development of successful cancer vaccines remains challenging. Only two vaccines have shown improved survival in advanced disease: sipuleucel-T and talimogene laherparepvec, which target specific antigens and utilize tumors in situ to prime responses. In this review, we examine the challenges and opportunities in developing therapeutic cancer vaccines.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Meeting Abstract
Oncology
Dove-Anna Johnson, Michelle Pleet, Joshua Aden Welsh, Sean Cook, Jason Savage, Nooshin Mirza Nasiri, Kevin A. Camphausen, Kenneth D. Aldape, James L. Gulley, Beverly A. Mock, Jay A. Berzofsky, Steve Jacobson, Jennifer C. Jones
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
JOURNAL OF CLINICAL ONCOLOGY
(2022)